What is the minimum level of cognitive symptoms that would prompt you to pursue biomarker testing required for anti-amyloid therapies for Alzheimer's?

I would require a clear diagnosis of MCI as defined by evidence of clearly impaired cognition on a valid neuropsychological test battery. I would not accept a patient based on a low-ish score on a single brief measure such as MMSE or MOCA as those tests ultimately lack specificity (as well as sensit...

All patients with mild cognitive impairment (MCI) should be offered biomarker testing to determine if they are eligible for anti-amyloid therapies. In-office tests such as MoCA and MMSE are sufficient to screen for MCI.

I offer amyloid biomarker testing in patients with MCI only if they qualify for amyloid therapies, if there is a genuine uncertainty about their diagnosis, and if having the biomarkers would change their management. I establish a diagnosis of MCI through clinical assessment and bedside cognitive ass...

Given the evidence that blood biomarkers are highly accurate, more reliable with the various mental status tests, and less costly and less invasive than CSF studies and PET, AND the fact that Alzheimer's progresses slowly over many years and that with an early diagnosis and treatment with anti-amylo...